Meta-analysis and trial sequential analysis of modified Sangbaipi Decoction for treating acute exacerbation of chronic obstructive pulmonary disease.
10.19540/j.cnki.cjcmm.20190419.501
- Author:
Wen-Jiang ZHENG
1
;
Zi-Jing PENG
1
;
Qian YAN
1
;
Chao-Yuan ZHANG
2
;
Bi-E LIU
1
;
Yu HONG
3
;
Xiao-Hong LIU
3
Author Information
1. the First Clinical College,Guangzhou University of Chinese Medicine Guangzhou 510405,China.
2. Clinical Medical College of Acupuncture Moxibustion and Rehabilitation,Guangzhou University of Chinese Medicine Guangzhou 510405,China.
3. the First Affiliated Hospital,Guangzhou University of Chinese Medicine Guangzhou 510405,China.
- Publication Type:Journal Article
- Keywords:
Meta-analysis;
Sangbaipi Decoction;
acute exacerbation;
chronic obstructive pulmonary disease;
modified;
trial sequential analysis
- MeSH:
Arterial Pressure;
Drugs, Chinese Herbal;
therapeutic use;
Forced Expiratory Volume;
Humans;
Lung;
Partial Pressure;
Pulmonary Disease, Chronic Obstructive;
drug therapy;
Randomized Controlled Trials as Topic;
Vital Capacity
- From:
China Journal of Chinese Materia Medica
2019;44(17):3806-3815
- CountryChina
- Language:Chinese
-
Abstract:
The randomized controlled trials about modified Sangbaipi Decoction in the treatment of acute exacerbation of chronic obstructive pulmonary disease( AECOPD) patients were collected from 7 databases( PubMed,CNKI,et al) from the establishment to December 5,2018. All the studies searched were strictly evaluated. Literatures were independently screened by two researchers according to the inclusion and exclusion criteria,and the methodological quality of included studies was evaluated. To systematically review the efficacy of modified Sangbaipi Decoction in treating AECOPD,the Meta-analysis and trial sequential analysis were conducted by using Stata/SE 14. 0 and TSA 0. 9. 5. 10 Beta,respectively. A total of 25 RCTs involving 1 784 patients were included. According to the results of Meta-analysis,compared with the control groups,the trial group had a higher clinical efficacy in AECOPD patients( RR =1. 18,95%CI[1. 13,1. 22],P = 0),improved pulmonary functions including forced expiratory volume in one second( FEV1,WMD =0. 44,95%CI[0. 01,0. 87],P = 0. 046),and the forced vital capacity( FVC,WMD = 0. 42,95%CI[0. 07,0. 22],P = 0),but no statistical significance in the percentage of forced expiratory volume in one second( FEV1%,P = 0. 067) and the first seconds breathing volume percentage of forced vital capacity( FEV1/FVC,P = 0. 238); it improved the arterial oxygen partial pressure( PaO2,SMD =0. 85,95%CI[0. 41,1. 30],P = 0) and decreased the arterial partial pressure of carbon dioxide( PaCO2,SMD =-0. 94,95% CI[-1. 70,-0. 18],P= 0. 016); and in terms of inflammatory markers,it improved the white blood cell count( WBC,WMD=-0. 94,95%CI[-1. 17,-0. 70],P = 0). The trial sequential analysis showed that the studies included with the improvement of clinical efficacy had passed the conventional and TSA threshold,so as to further confirm the evidence. According to the findings,in addition to conventional Western medicine treatment,modified Sangbaipi Decoction could improve the efficiency in treating acute exacerbation patients with chronic obstructive pulmonary disease,increase PaO2,and decrease PaCO2,with a high safety but no effect on pulmonary function. However,restricted by the low quality of studies included,this conclusion shall be further verified by more high-quality clinical trials.
